BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 22167243)

  • 1. Vancomycin-intermediate Staphylococcus aureus selected during vancomycin therapy of experimental endocarditis are not detected by culture-based diagnostic procedures and persist after treatment arrest.
    Moreillon P; Bizzini A; Giddey M; Vouillamoz J; Entenza JM
    J Antimicrob Chemother; 2012 Mar; 67(3):652-60. PubMed ID: 22167243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.
    Hegde SS; Skinner R; Lewis SR; Krause KM; Blais J; Benton BM
    J Antimicrob Chemother; 2010 Apr; 65(4):725-8. PubMed ID: 20139142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
    Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
    J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
    Madrigal AG; Basuino L; Chambers HF
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The first pediatric case of Staphylococcus aureus with heterogenous resistant to vancomycin endocarditis in Thailand.
    Phongsamart W; Srifeungfung S; Tiensasitorn C; Vanprapar N; Chearskul S; Chokephaibulkit K
    J Med Assoc Thai; 2005 Nov; 88 Suppl 8():S264-8. PubMed ID: 16856450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative activity of cloxacillin and vancomycin against methicillin-susceptible Staphylococcus aureus experimental endocarditis.
    Fernández Guerrero ML; de Górgolas M
    J Antimicrob Chemother; 2006 Nov; 58(5):1066-9. PubMed ID: 16931540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA).
    Howden BP
    Intern Med J; 2005 Dec; 35 Suppl 2():S136-40. PubMed ID: 16271057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
    Entenza JM; Que YA; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3076-83. PubMed ID: 11600359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides.
    Leonard SN; Rossi KL; Newton KL; Rybak MJ
    J Antimicrob Chemother; 2009 Mar; 63(3):489-92. PubMed ID: 19136530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure.
    Kelley PG; Gao W; Ward PB; Howden BP
    J Antimicrob Chemother; 2011 May; 66(5):1057-60. PubMed ID: 21393156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).
    Appelbaum PC
    Int J Antimicrob Agents; 2007 Nov; 30(5):398-408. PubMed ID: 17888634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals.
    Sader HS; Jones RN; Rossi KL; Rybak MJ
    J Antimicrob Chemother; 2009 Nov; 64(5):1024-8. PubMed ID: 19744978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the clinical features, bacterial genotypes and outcomes of patients with bacteraemia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible S. aureus.
    Park KH; Kim ES; Kim HS; Park SJ; Bang KM; Park HJ; Park SY; Moon SM; Chong YP; Kim SH; Lee SO; Choi SH; Jeong JY; Kim MN; Woo JH; Kim YS
    J Antimicrob Chemother; 2012 Aug; 67(8):1843-9. PubMed ID: 22535621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.
    Charles PG; Ward PB; Johnson PD; Howden BP; Grayson ML
    Clin Infect Dis; 2004 Feb; 38(3):448-51. PubMed ID: 14727222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia.
    Howden BP; Johnson PD; Ward PB; Stinear TP; Davies JK
    Antimicrob Agents Chemother; 2006 Sep; 50(9):3039-47. PubMed ID: 16940100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The quest to identify heterogeneously resistant vancomycin-intermediate Staphylococcus aureus strains.
    Tenover FC
    Int J Antimicrob Agents; 2010 Oct; 36(4):303-6. PubMed ID: 20674281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
    Leonard SN; Rybak MJ
    J Antimicrob Chemother; 2009 Jan; 63(1):155-60. PubMed ID: 18984644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo activity of evernimicin (SCH 27899) against methicillin-resistant Staphylococcus aureus in experimental infective endocarditis.
    Boucher HW; Thauvin-Eliopoulos C; Loebenberg D; Eliopoulos GM
    Antimicrob Agents Chemother; 2001 Jan; 45(1):208-11. PubMed ID: 11120967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Investigation of glycopeptide resistance in methicillin resistant staphylococcal isolates].
    Hoşgör Limoncu M; Ermertcan S; Taşli H; Kurutepe S
    Mikrobiyol Bul; 2007 Oct; 41(4):511-6. PubMed ID: 18173069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Xpert™ MRSA/SA Blood Culture assay for the detection of Staphylococcus aureus including strains with reduced vancomycin susceptibility from blood culture specimens.
    Kelley PG; Grabsch EA; Farrell J; Xie S; Montgomery J; Mayall B; Howden BP
    Diagn Microbiol Infect Dis; 2011 Jul; 70(3):404-7. PubMed ID: 21497042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.